leisure time -WSS

leisure time

author：Wikipedia 2025-09-07 06:53:38 - browse：7264

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： BIO selects John Crowley as new CEO

focus

WSS

Pumping milk in bathrooms at health conferences is common

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

FDA investigates CAR

Future doctors need a strong humanities education

Diagnostic tests are hitting their mathematical limits

TikTok, Instagram influencers need more rules for drug ads

hotspot

leisure time

focus

Medicare details structure of new drug price negotiation program

Printout prescription drug information shouldn’t go digital

Moonlake's readout produced a cash windfall. Risks remain

Prior authorization reform is both possible and imperative

Bright Health sells Medicare Advantage business to Molina

Future doctors need a strong humanities education

Alkermes shareholders re

What don’t we know about an Alzheimer’s drug side effect?

State Dept. review finds Biden bears some blame for Afghanistan failures

Disappointing trial forces Pfizer to pivot on obesity medicine plans

hotspot

CDC director unscathed in first congressional testimony

CVS is on a mission to consolidate health care. Will it work?

ReNAgade cuts staff seven months after raising $300 million

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Cigna, Humana reportedly in talks to merge

With clinical trial data readouts, here's how to spot spin

focus

explore

entertainment

Wikipedia